Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1150889

	registered interest
	date	21/10/2019
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Immigration: Afghanistan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what representations she has received on delays experienced by Afghan Sikh refugees in the UK immigration system.
	tabling member constituency	Feltham and Heston
	tabling member printed	Seema Malhotra
	uin	2757
	answer	answer is ministerial correction date of answer 05/11/2019 answer text <p><strong><em>It has not proved possible to respond to the hon. Member in the time available before Dissolution</em></strong>.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 05/11/2019 16:57:17 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4253 label Biography information for Seema Malhotra

1141382

	registered interest
	date	23/07/2019
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Visas: Rugby
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, how many non-UK professional male rugby players sponsored by (a) the Rugby Football Union and (b) rugby clubs issued governing body endorsements to become a sponsor have received Tier 2 and Tier 5 migrant visas in each of the last 10 years.
	tabling member constituency	Feltham and Heston
	tabling member printed	Seema Malhotra
	uin	281085
	answer	answer is ministerial correction date of answer 31/07/2019 answer text <p>The Home Office does not collate or publish the information requested.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 31/07/2019 15:23:16 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4253 label Biography information for Seema Malhotra

1141383

	registered interest
	date	23/07/2019
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Visas: Migrant Workers
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what the requirements are for an organisation to qualify to sponsor Tier 2 and Tier 5 visas; and how many organisations meet those qualifications.
	tabling member constituency	Feltham and Heston
	tabling member printed	Seema Malhotra
	uin	281086
	answer	answer is ministerial correction date of answer 31/07/2019 answer text <p>The requirements to become a sponsor and maintain this status are set out in the Tiers 2 and 5: guidance for sponsors. Currently, there are more than 30,000 organisations that are licenced sponsors.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 31/07/2019 15:05:38 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4253 label Biography information for Seema Malhotra

1141384

	registered interest
	date	23/07/2019
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Visas: Rugby
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what assessment he has made of the effect of the level of funding for women's rugby clubs in English women’s rugby championships and premierships on the ability of non-UK professional women rugby players to receive Tier 2 and Tier 5 migrant visas; and what other options are available for non-UK women rugby players to remain in the UK.
	tabling member constituency	Feltham and Heston
	tabling member printed	Seema Malhotra
	uin	281087
	answer	answer is ministerial correction date of answer 31/07/2019 answer text <p>The funding of UK sports is a matter for the Department of Culture, Media and Sport.</p><p>Tiers 2 and 5 are our principle immigration routes for those wishing to play professional sport in the UK. Other visa options may be open to some migrants depending on their individual circumstances.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 31/07/2019 15:25:00 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4253 label Biography information for Seema Malhotra

1136653

	registered interest
	date	03/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the prevalence of (a) Type 1 and (b) Type 2 diabetes in each local authority area in each of the last three years; what steps his Department is taking to tackle the prevalence of diabetes; and what assessment he has made of the effectiveness of his Department's policy on tackling diabetes.
	tabling member constituency	Feltham and Heston
	tabling member printed	Seema Malhotra
	uin	272840
	answer	answer is ministerial correction date of answer 12/07/2019 answer text <p>Data on the prevalence of type 1 and type 2 diabetes is not available at local authority level.</p><p>The prevalence of both type one and type two diabetes, combined, is monitored and published via the Quality and Outcomes Framework (QOF) and the National Diabetes Audit (NDA) provides information on the number with each condition separately at clinical commissioning group and general practice level. The QOF can be viewed at the following link:</p><p><a href="https://qof.digital.nhs.uk/" target="_blank">https://qof.digital.nhs.uk/</a></p><p>The NDA can be viewed at the following link:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit</a></p><p>Steps to reduce the increase in the prevalence of type 2 diabetes are being led via the Healthier You NHS Diabetes Prevention Programme. This programme can be viewed at the following link:</p><p><a href="https://www.england.nhs.uk/diabetes/diabetes-prevention/" target="_blank">https://www.england.nhs.uk/diabetes/diabetes-prevention/</a></p><p>Significant funding and commitments to improving services for those with type 1 and type 2 diabetes have also been made in the NHS Long Term Plan. The NHS Long Term Plan can be viewed at the following link:</p><p><a href="https://www.longtermplan.nhs.uk/" target="_blank">https://www.longtermplan.nhs.uk/</a></p><p>A first progress report covering early implementation of the Healthier You Diabetes Prevention Programme, including numbers of referrals and uptake in its first year, was published as a short report in Diabetic Medicine and can be accessed at the following link:</p><p><a href="https://onlinelibrary.wiley.com/doi/full/10.1111/dme.13562" target="_blank">https://onlinelibrary.wiley.com/doi/full/10.1111/dme.13562</a></p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 12/07/2019 11:23:20 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4253 label Biography information for Seema Malhotra

1136238

	registered interest
	date	02/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Greater London
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what comparative assessment his Department has made between the annual cancer mortality rate in (a) the London borough of Hounslow and (b) London in each of the last five years; and what steps his Department is taking to tackle cancer mortality in (i) the London borough of Hounslow and (ii) London.
	tabling member constituency	Feltham and Heston
	tabling member printed	Seema Malhotra
	uin	272196
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>The information is not available in the format requested.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/07/2019 11:08:14 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4253 label Biography information for Seema Malhotra

1136290

	registered interest
	date	02/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Maraviroc
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the (a) adequacy of NHS procurement options for and (b) the affordability of Maraviroc.
	tabling member constituency	Feltham and Heston
	tabling member printed	Seema Malhotra
	uin	272207
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>NHS England runs a competitive framework tender process to assess availability and cost of drugs used to treat HIV. Maraviroc is currently commissioned and procured for HIV nationally through a tender framework by NHS England and NHS Improvement. The affordability of Maraviroc is similar to comparable HIV treatments.</p><p> </p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/07/2019 16:22:18 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4253 label Biography information for Seema Malhotra

1136291

	registered interest
	date	02/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Maraviroc: Progressive Multifocal Leukoencephalopathy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment NHS England has made of the availability of Maraviroc to patients with progressive multifocal leukoencephalopathy.
	tabling member constituency	Feltham and Heston
	tabling member printed	Seema Malhotra
	uin	272208
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>We are informed by NHS England and NHS Improvement that it does not commission Maraviroc for progressive multifocal leukoencephalopathy as there is currently insufficient evidence to support its use in this condition.</p><p>NHS England and NHS Improvement have published do not commission policy for ‘Natalizumab-induced progressive multifocal leukoencephalopathy in relation to immune reconstitution inflammatory syndrome in multiple sclerosis.’</p><p>Due to a lack of evidence and as it is considered experimental, it is not currently commissioned for this indication.</p><p>Further information is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2018/03/maraviroc-for-ms-urgent-policy-statement.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2018/03/maraviroc-for-ms-urgent-policy-statement.pdf</a></p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/07/2019 16:06:26 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4253 label Biography information for Seema Malhotra

1135903

	registered interest
	date	01/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Liothyronine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the value for money of prescribing Liothyronine (T3) on the NHS.
	tabling member constituency	Feltham and Heston
	tabling member printed	Seema Malhotra
	uin	271506
	answer	answer is ministerial correction date of answer 09/07/2019 answer text <p>The Department has made no assessment. Clinical commissioning groups (CCGs) are responsible for the planning, commissioning and access to health care services for their local area.</p><p> </p><p>NHS England and NHS Improvement are working closely with CCGs on the prescribing of liothyronine to support them with the implementation of guidance for CCGs on items which should not be routinely prescribed in primary care.</p><p>This guidance includes recommendations on the use of liothyronine in line with the British Thyroid Association, who advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction. In these circumstances, where levothyroxine has failed and in line with this guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least three months duration of the drug.</p><p>Further guidance on the prescribing of liothyronine has been published by the Regional Medicines Optimisation Committee. The aim of the guidance is to make best practice on the prescribing of liothyronine clearer. CCGs are expected to have regard to national guidance, and are responsible for developing their own local approaches to its implementation taking into account local priorities and needs.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 271507 271508 question first answered 09/07/2019 13:11:47 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4253 label Biography information for Seema Malhotra

1135904

	registered interest
	date	01/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Liothyronine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure access to Liothyronine on the NHS as an alternative to Levothyroxine.
	tabling member constituency	Feltham and Heston
	tabling member printed	Seema Malhotra
	uin	271507
	answer	answer is ministerial correction date of answer 09/07/2019 answer text <p>The Department has made no assessment. Clinical commissioning groups (CCGs) are responsible for the planning, commissioning and access to health care services for their local area.</p><p> </p><p>NHS England and NHS Improvement are working closely with CCGs on the prescribing of liothyronine to support them with the implementation of guidance for CCGs on items which should not be routinely prescribed in primary care.</p><p>This guidance includes recommendations on the use of liothyronine in line with the British Thyroid Association, who advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction. In these circumstances, where levothyroxine has failed and in line with this guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least three months duration of the drug.</p><p>Further guidance on the prescribing of liothyronine has been published by the Regional Medicines Optimisation Committee. The aim of the guidance is to make best practice on the prescribing of liothyronine clearer. CCGs are expected to have regard to national guidance, and are responsible for developing their own local approaches to its implementation taking into account local priorities and needs.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 271506 271508 question first answered 09/07/2019 13:11:47 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4253 label Biography information for Seema Malhotra